title: alpha-Phenyl-n-tert-butyl-nitrone attenuates hypoxic-ischemic white matter injury in the neonatal rat brain.
abstract: White matter of the neonatal brain is highly sensitive to hypoxic-ischemic insult. The susceptibility of premature oligodendrocytes (OLs) to free radicals (FRs) produced during hypoxia-ischemia (HI) has been proposed as one of the mechanisms involved. To test this hypothesis, and to further investigate if the FR scavenger alpha-phenyl-N-tert-butyl-nitrone (PBN) attenuates hypoxic-ischemic white matter damage (WMD), postnatal day 4 (P4) SD rats were subjected to bilateral common carotid artery ligation (BCAL), followed by 8% oxygen exposure for 20 min. Pathological changes were evaluated on P6 and P9, 2 and 5 days after the HI insult. HI caused severe WMD including rarefaction, necrosis and cavity formation in the corpus callosum, external and internal capsule areas. OL injury was evidenced by degeneration of O4 positive OLs on P6. Disrupted myelination was verified by decreased immunostaining of myelin basic protein (MBP) on P9. Axonal injury was demonstrated by increased amyloid precursor protein (APP) immunostaining on both P6 and P9. Two lipid peroxidation end products, malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), showed a one-fold elevation within 1-24 h following HI. 4-HNE immunostaining was found to specifically localize in the white matter area. Furthermore, pyknotic O4+ OLs were double-labeled with 4-HNE. These findings suggest that FRs are involved in the pathogenesis of neonatal WMD. PBN (100 mg/kg, i.p.) treatment alleviated the pathological changes of WMD following HI. It improved the survival of O4 positive OLs, attenuated hypomyelination and reduced axonal damage. PBN treatment also decreased the brain concentration of MDA/4-HNE and positive 4-HNE staining in the white matter area. These findings indicate that in the current WMD model, PBN protects both OLs and axons, the two main components in the white matter, from neonatal HI insult. FR scavenging appears to be the primary mechanism underlying its neuroprotective effect.
authors.affiliation: Department of Pediatrics, Division of Newborn Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.
authors.forename: Shuying
authors.initials: S
authors.lastname: Lin
authors.forename: Philip G
authors.initials: PG
authors.lastname: Rhodes
authors.forename: Manping
authors.initials: M
authors.lastname: Lei
authors.forename: Feng
authors.initials: F
authors.lastname: Zhang
authors.forename: Zhengwei
authors.initials: Z
authors.lastname: Cai
mesh_terms: D000367:Age Factors; D000447:Aldehydes / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D000943:Antigens, Differentiation / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000254:growth & development / Q000473:pathology; D002452:Cell Count / Q000379:methods; D002470:Cell Survival / Q000187:drug effects; D003497:Cyclic N-Oxides; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D020925:Hypoxia-Ischemia, Brain / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D007150:Immunohistochemistry / Q000379:methods; D020244:Infarction, Middle Cerebral Artery / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D008315:Malondialdehyde / Q000378:metabolism; D004676:Myelin Basic Protein / Q000378:metabolism; D009589:Nitrogen Oxides / Q000627:therapeutic use*; D009836:Oligodendroglia / Q000378:metabolism / Q000473:pathology; D051381:Rats; D013194:Staining and Labeling / Q000379:methods; D013997:Time Factors
chemical_list: D000447:Aldehydes; D016229:Amyloid beta-Peptides; D000943:Antigens, Differentiation; D003497:Cyclic N-Oxides; D016166:Free Radical Scavengers; D004676:Myelin Basic Protein; D009589:Nitrogen Oxides; C488961:oligodendrocyte O antigen, rat; C029217:phenyl-N-tert-butylnitrone; D008315:Malondialdehyde; C027576:4-hydroxy-2-nonenal